Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of VV119 in Healthy Volunteers
NCT07240636Phase 1Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VV119 in Insomnia (2 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Treatment-Emergent Adverse Events at 7 days, Maximum Plasma Concentration at 480 hours and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
VV119
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT07240636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240636.